Are Monoclonal Antibodies Beneficial for Patients Hospitalized with COVID-19?

Intravenous therapy with casirivimab and imdevimab was associated with reduced 28-day mortality in patients hospitalized with COVID-19 who were negative for anti-spike antibodies.

Anti–SARS-CoV-2 monoclonal antibodies are effective at preventing progression to severe COVID-19 and as prophylactic agents (NEJM JW Infect Dis Nov 2021 and N Engl J Med 2021 Dec 2; 385:e81); but what about patients already hospitalized with COVID-19? In a platform trial at 127 U.K. hospitals, investigators randomized such patients to receive usual care with or without an infusion of casirivimab and imdevimab (4 g each). The primary endpoint was 28-day mortality. During the trial (but before unmasking of results), the analysis was revised to test the efficacy of this combination first in patients who were seronegative at baseline for anti–SARS-CoV-2 spike antibodies, and second in the overall study population.

Among 9785 enrollees (mean age,…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Are Monoclonal Antibodies Beneficial for Patients Hospitalized with COVID-19?

Topics

Reviewing Author